Expression of the chemokine CXCL14 and cetuximab-dependent tumour suppression in head and neck squamous cell carcinoma.

摘要: Cetuximab, a monoclonal antibody against the epidermal growth factor receptor (EGFR), has been successfully used to treat some patients with colorectal cancer and those head neck squamous cell carcinoma (HNSCC). For effective treatment, it is essential first identify cetuximab-responsive patients. The level of EGFR expression and/or presence mutations in signalling molecules downstream pathway have reported be determining factors for cetuximab responsiveness patients; however, limited data HNSCC We previously that chemokine CXCL14 exhibits tumour-suppressive effects xenografted cells, which may classified into two groups, CXCL14-expressing non-expressing cells under serum-starved culture conditions. Here we employed HSC-3 CXCL14-non-expressing YCU-H891 as representatives groups compared their responses various tumours initiated by expressed vivo vitro, was suppressed injection tumour-bearing mice; neither nor cetuximab-dependent suppression xenograft tumour observed cells. Both types type harboured cetuximab-resistant colon inhibition extracellular signal-regulated kinase (ERK) increased levels messenger RNA (mRNA) but not also promoter region hypermethylated, demethylation treatment 5-aza-2'-deoxycytidine restored mRNA cetuximab-mediated suppression. Finally, when were engineered express ectopically doxycycline. These results indicate good predictive biomarker